Trandolapril/verapamil

Drug Profile

Trandolapril/verapamil

Alternative Names: Ocadrik; Tarka; Verapamil/trandolapril

Latest Information Update: 22 Jan 2013

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer AbbVie; Sanofi
  • Class Antihypertensives; Indoles
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 03 Jun 2004 Aventis granted Abbott Laboratories the remaining commercial rights for trandolapril, except in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top